10-Q: Brainstorm Cell Therapeutics Faces Financial Hurdles Amidst Clinical Development

Brainstorm Cell Therapeutics Inc. reported continued operating losses and a substantial accumulated deficit in its Q2 2026 filing, highlighting ongoing capital needs and challenges following its Nasdaq delisting.

Summary

• Brainstorm Cell Therapeutics Inc. reported a net loss of $3.86 million for the three months ended June 30, 2026, and $5.98 million for the six months ended June 30, 2026.
• The company has an accumulated deficit of approximately $243 million as of June 30, 2026.
• Cash and cash equivalents stood at $209,000 as of June 30, 2026.
• The company received a delisting notification from Nasdaq in July 2025 and now trades on the OTCQB Venture Market.
• Several lawsuits, including a securities class action and derivative actions, are ongoing.
• The company continues to rely on financing activities, including private placements and short-term loans, to fund operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the company's continued operating losses, significant accumulated deficit, and ongoing need for substantial capital raises, coupled with the delisting from Nasdaq and ongoing legal proceedings.

Positives

• The company has secured a Special Protocol Assessment (SPA) agreement with the FDA for the design of its Phase 3b trial of NurOwn in ALS.
• Alignment has been reached with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of the Phase 3b trial.
• The company continues to advance its research into NurOwn and exosome-based technologies for neurodegenerative diseases.
• The company has secured financing through various private placements and short-term loans in the period.

Negatives

• The company reported a net loss of $3.86 million for Q2 2026 and $5.98 million for the first six months of 2026.
• An accumulated deficit of approximately $243 million exists as of June 30, 2026.
• Cash and cash equivalents were only $209,000 as of June 30, 2026, indicating a critical need for further funding.
• The company's common stock was delisted from Nasdaq and now trades on the OTCQB Venture Market, potentially impacting liquidity and investor access.
• Significant ongoing legal proceedings, including a securities class action and derivative lawsuits, pose financial and operational risks.
• The company has identified a material weakness in its internal control over financial reporting related to short-term loan execution.
• The company's ability to continue as a going concern is subject to substantial doubt, contingent on raising additional capital.

Risks

• The company's ability to continue as a going concern is uncertain and depends on its ability to raise substantial additional capital.
• The delisting from Nasdaq and trading on the OTCQB Venture Market may negatively impact the liquidity and price of its common stock.
• Ongoing securities class action and derivative lawsuits could result in significant financial liabilities and management distraction.
• The company faces risks related to the regulatory approval process for NurOwn, including potential delays or rejections from the FDA.
• The success of its product development programs and research is subject to inherent uncertainties and risks.
• The company may not be able to secure future financing on acceptable terms, or at all, which is critical for its continued operations.
• A material weakness in internal controls over financial reporting could lead to undetected misstatements in financial statements.

Future Outlook

The company anticipates continued losses from clinical development and regulatory activities, necessitating substantial future financing. Management is exploring various capital-raising alternatives, including equity and debt offerings, to fund operations, Phase 3b trials, commercialization efforts, and potential future trials for other indications. The ability to secure this financing is critical for the company's continued operations.

Management Comments

• The Company has incurred operating losses since its inception and expects to continue to incur operating losses for the near-term.
• Management's plan includes raising funds from outside potential investors, however, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.
• The Company has identified a material weakness in its internal control over financial reporting related to short-term loans initiation, review, authorization and execution controls.
• Brainstorm remains committed to the ALS Community and is actively exploring the next steps in support of NurOwn, including publication of emerging clinical data and development of a protocol for an additional clinical study.

Industry Context

StockSavvy.ai notes that Brainstorm Cell Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on rare and neurodegenerative diseases. The company's reliance on clinical trial success and regulatory approvals, coupled with significant R&D expenses, is typical for the industry. However, the delisting from Nasdaq and ongoing legal challenges present unique headwinds not commonly seen in companies at this stage of development.

Comparison to Industry Standards

• Companies in the late-stage biotechnology sector often require substantial capital raises to fund clinical trials and regulatory submissions, similar to Brainstorm's ongoing need for financing.
• The typical path to market for novel cell therapies involves extensive clinical trials (Phase 1, 2, 3) and rigorous FDA review, a process Brainstorm has navigated with its NurOwn candidate.
• Many biotechnology firms face challenges with cash burn and achieving profitability due to high R&D costs and long development timelines, a situation reflected in Brainstorm's accumulated deficit and net losses.
• The biotechnology industry is subject to significant regulatory scrutiny, and setbacks in clinical trials or regulatory submissions, as experienced by Brainstorm with its BLA for ALS, are not uncommon.
• The use of stock-based compensation is a standard practice in the biotech industry to attract and retain talent, as evidenced by Brainstorm's stock option and restricted stock awards.

Management Changes

Legal Proceedings

• A putative securities class action complaint alleges violations of Section 10(b) and Rule 10b-5 of the Exchange Act related to statements about NurOwn for ALS and FDA submissions.
• Four purported shareholders filed derivative action complaints alleging breach of fiduciary duty and unjust enrichment against officers and directors.
• 3D Communications, LLC filed a lawsuit for breach of contract, seeking approximately $0.5 million in allegedly unpaid invoices.
• Brainstorm Cell Therapeutics Ltd. (Israeli subsidiary) was served with a statement of claim alleging breach of an agreement for clean room usage, seeking approximately $0.7 million.

Related Party Transactions

• In October 2025, the Company entered into a loan agreement with a related party for a principal amount of $220,000, bearing interest at 8.5%, due by December 31, 2026.
• On June 15, 2026, the Company entered into a loan agreement with a related party for a principal amount of $15,000, bearing interest at 8.5%, due by July 30, 2027.

Stakeholder Impact

• Shareholders face potential dilution from ongoing capital raises and uncertainty due to the Nasdaq delisting and ongoing legal proceedings.
• Employees may be impacted by the company's financial instability and the material weakness in internal controls.
• Creditors and lenders face increased risk given the company's liquidity challenges and reliance on short-term financing.
• The company's ability to continue operations impacts patients and the broader ALS and neurodegenerative disease communities who rely on its investigational therapies.

Next Steps

• Continue to fund operations through capital raises.
• Conduct a Phase 3b trial for NurOwn in ALS, with FDA agreement on protocol design.
• Pursue commercialization of NurOwn for ALS.
• Consider future trials for other indications.
• Implement remediation plan for material weakness in internal controls.

Key Dates

Recommendation

The company's core technology (NurOwn) shows promise in specific patient subgroups and has secured FDA agreement on a Phase 3b trial protocol, which is a positive development. However, the critical liquidity situation, Nasdaq delisting, ongoing litigation, and a material weakness in internal controls present significant risks. A 'hold' recommendation reflects a balance between the potential upside of successful clinical development and the substantial downside risks associated with the company's financial and operational challenges.

Keywords

NurOwn, ALS, Neurodegenerative Diseases, Biotechnology, Clinical Trials, FDA, Cell Therapy, Biologics License Application